Q-omics provides the consensus-scored ADGRL2 profile across patient tissues and cancer cell-line models. ADGRL2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, ADGRL2 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, ADGRL2 protein abundance shows 31,236 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BLCA, THCA, and LSCC as cancer lineages where ADGRL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADGRL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADGRL2 survival associations across molecular data types. ADGRL2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (10) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADGRL2 RNA expression–survival associations across cancer types. High ADGRL2 expression shows unfavorable associations in BLCA, UVM, KIRP, LGG and STAD, but favorable associations in KIRC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for ADGRL2 RNA expression.
This table summarizes ADGRL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 9. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ADGRL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADGRL2 shows lower tumor expression in THCA, HNSC, KICH, LUAD, LUSC and BRCA. The THCA box plot shows higher ADGRL2 RNA expression in normal versus tumor tissue (log2 FC = −2.580, t-test p < 0.001).
This table shows molecular features associated with ADGRL2 in patient tissues and cancer cell lines. In patient samples, ADGRL2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ADGRL2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
